SCHEMBL16740293

SCHEMBL16740293

Cc1nc2ncccc2n1-c1cncc(Nc2ccc(C(F)(F)F)c(F)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.37
DHODH Q02127 1/20 0.36
BMI1 P35226 3/20 0.36
GALR2 O43603 1/20 0.35
GALR1 P47211 1/20 0.35
CYP11B2 P19099 2/20 0.34
CYP11B1 P15538 1/20 0.34
CDK2 P24941 2/20 0.33
CDK4 P11802 1/20 0.33
BUB1 O43683 1/20 0.33
GSK3B P49841 1/20 0.32
GRM4 Q14833 1/20 0.32
PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16739732 0.89 BMI1 (0.39) TRPV1DHODHBMI1CYP11B2CYP11B1
SCHEMBL16740417 0.85 BMI1 (0.50) DHODHBMI1CYP11B2CYP11B1
SCHEMBL16740326 0.85 BMI1 (0.49) TRPV1DHODHBMI1PDE10A
SCHEMBL16747989 0.83 BMI1 (0.38) BMI1GALR2GALR1BUB1GRM4
SCHEMBL16747809 0.82 BMI1 (0.42) DHODHBMI1CYP11B2CYP11B1BUB1
SCHEMBL16740316 0.81 KCNH2 (0.49) DHODHBMI1
SCHEMBL16740474 0.79 BMI1 (0.43) TRPV1DHODHBMI1CYP11B2CYP11B1
SCHEMBL16740380 0.77 BMI1 (0.52) BMI1GALR2PDE10A
SCHEMBL16740038 0.77 BMI1 (0.51) BMI1CDK2
SCHEMBL16740015 0.75 BMI1 (0.52) DHODHBMI1CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US claimed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US claimed
EP-3071553-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC Therapeutics, Inc. (US) 2016-09-28 EP claimed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B TRPV1 4697/4885DHODH 3196/4885BMI1 1/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B TRPV1 4697/4885DHODH 3196/4885BMI1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.